Coherus BioSciences (NASDAQ: CHRS)
Coherus BioSciences Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Coherus BioSciences Company Info
Coherus BioSciences, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of biosimilar therapeutics. Its products include UDENYCA and Coherus COMPLETE. The company was founded by Dennis M. Lanfear, Stuart E. Builder, Dr. Alan Herman, Doug Farrar and Steve Glover in September 2010 and is headquartered in Redwood City, CA.
News & Analysis
Why Coherus Biosciences Stock Tumbled on Thursday
The company fell well short of expectations for its fourth quarter.
Why Coherus BioSciences Stock Jumped Today
As promised, Coherus is using the proceeds of a recent divestiture to pay down debt and reduce interest expenses.
Why Coherus BioSciences Stock Is Sinking Today
The positive reaction to Coherus' sale of its ophthalmology franchise to Sandoz didn't last long.
Why Coherus Biosciences Popped Today
Coherus is divesting its non-core ophthalmology franchise.
Why Coherus BioSciences Stock Jumped Today
Coherus finally received FDA approval for its Udenyca OnBody injector system.
Why Coherus BioSciences Was Plummeting This Week
The company has been punished harshly for a worse-than-expected quarter.
Why Coherus Biosciences Stock Dropped Today
Coherus missed estimates for the third quarter and lowered its full-year outlook.
Why Coherus BioSciences Stock Soared Today
Coherus and Junshi Biosciences announced the long-awaited FDA approval of NPC drug Loqtorzi. Here's what investors need to know.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.